Bremer Trust National Association purchased a new stake in shares of Iqvia Holdings Inc (NYSE:IQV) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 14,764 shares of the medical research company’s stock, valued at approximately $1,445,000.
A number of other large investors also recently added to or reduced their stakes in IQV. Exxonmobil Investment Management Inc. TX purchased a new stake in Iqvia during the 4th quarter valued at $2,266,000. DnB Asset Management AS purchased a new stake in Iqvia during the 4th quarter valued at $8,813,000. First Citizens Bank & Trust Co. purchased a new stake in Iqvia during the 4th quarter valued at $1,067,000. Franklin Street Advisors Inc. NC purchased a new stake in Iqvia during the 4th quarter valued at $7,446,000. Finally, Nisa Investment Advisors LLC purchased a new stake in Iqvia in the fourth quarter worth $920,000. Institutional investors own 95.78% of the company’s stock.
In other news, Director John Connaughton sold 1,163,191 shares of the stock in a transaction on Thursday, November 30th. The stock was sold at an average price of $102.00, for a total transaction of $118,645,482.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider James H. Erlinger III sold 10,000 shares of the stock in a transaction on Wednesday, December 20th. The stock was sold at an average price of $101.21, for a total value of $1,012,100.00. The disclosure for this sale can be found here. Insiders have sold a total of 8,806,558 shares of company stock worth $898,722,108 in the last three months. Corporate insiders own 6.40% of the company’s stock.
Iqvia (NYSE:IQV) last posted its quarterly earnings results on Thursday, October 26th. The medical research company reported $1.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.14 by $0.05. Iqvia had a return on equity of 12.60% and a net margin of 0.58%. The business had revenue of $2.02 billion for the quarter, compared to the consensus estimate of $2.01 billion. During the same quarter in the prior year, the company earned $1.00 EPS. The business’s revenue was up 77.6% compared to the same quarter last year. equities analysts forecast that Iqvia Holdings Inc will post 4.62 EPS for the current fiscal year.
A number of analysts have weighed in on the company. Mizuho lowered Iqvia from a “buy” rating to a “neutral” rating and set a $90.00 target price on the stock. in a research note on Thursday, November 9th. SunTrust Banks reiterated a “hold” rating and issued a $114.00 target price on shares of Iqvia in a research note on Friday, November 3rd. KeyCorp reiterated a “buy” rating and issued a $100.00 target price on shares of Iqvia in a research note on Sunday, September 24th. Credit Suisse Group reiterated an “outperform” rating and issued a $110.00 target price (up previously from $98.00) on shares of Iqvia in a research note on Monday, October 16th. Finally, Zacks Investment Research lowered Iqvia from a “buy” rating to a “hold” rating in a research note on Friday, November 3rd. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $106.94.
IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.